Core Opportunity and Financial Performance - The company has a total addressable market (TAM) exceeding $3 billion, with significant opportunities in products like Hyalofast and Cingal [1][5] - Anika reported positive EBITDA of approximately $5 million and over $11 million in operating cash flow for 2025, supported by a strong balance sheet with more than $50 million in cash and no debt [2][5] Product Portfolio and Market Strategy - Anika has focused on hyaluronic acid (HA) technologies for 33 years, primarily in osteoarthritis pain management and regenerative medicine, generating strong profitability and cash flow [2][3] - The core products, Orthovisc and Monovisc, provide long-lasting pain relief and are characterized as high molecular weight products, contributing significantly to free cash flow [6][7] Revenue Channels and Growth Outlook - The revenue mix is divided between the OEM channel, which faces pricing pressure and is expected to be flat to modestly lower in 2026, and the commercial channel, which is projected to grow in the mid-teens with guidance of 10-20% growth for 2026 [4][15] - The commercial channel has shown consistent growth, increasing from $26 million in 2021 to $48 million in 2025, with expectations for continued growth driven by international OA pain products and the U.S. regenerative business [15] Regulatory and Pipeline Developments - Cingal, a combination product, has completed three Phase 3 trials and is expected to file for NDA submission with the FDA after completing necessary studies [13][14] - The Integrity Implant System, launched in 2023, generated about $2 million in sales in 2024 and is expected to reach approximately $6 million in 2025, exceeding initial expectations [9][8] Competitive Landscape and R&D Focus - Anika is focused on R&D investments related to Cingal and other pipeline products, aiming to differentiate its offerings in a competitive HA market [17] - The company is in discussions with the FDA regarding its PMA submission for Hyalofast, which has over 15 years of clinical data and is positioned as a single-stage surgery product [12][10]

Anika Therapeutics Conference Call Summary Company Overview - **Company**: Anika Therapeutics (NasdaqGS:ANIK) - **Industry**: Medical Device, specifically focused on hyaluronic acid-based technologies for joint preservation - **CEO**: Steve Griffin - **Established**: 33 years ago, primarily focused on hyaluronic acid products [2][3] Core Business and Financials - **Product Portfolio**: - Osteoarthritis (OA) pain management products: Orthovisc, Monovisc, Cingal - Regenerative Solutions: Integrity, Hyalofast - **Financial Position**: - Over $50 million in cash and no debt [3][21] - Positive EBITDA and free cash flow reported for 2025 [3][20] - **Revenue Growth**: - Commercial channel revenue grew from $26 million in 2021 to $48 million in 2025, with expectations of 10% to 20% growth in 2026 [17][18] - Total addressable market (TAM) estimated at over $3 billion [5] Product Details - **OA Pain Management Portfolio**: - **Orthovisc and Monovisc**: Combined TAM of over $1 billion, market leaders in the U.S. for OA pain treatment [5][6] - **Cingal**: Next-generation product combining Monovisc with a steroid, expected to unlock an additional $1 billion TAM [6][14] - **Regenerative Solutions Portfolio**: - **Integrity**: Launched in 2023, with sales of $6 million in 2025, targeting a $230 million market [10][18] - **Hyalofast**: Established outside the U.S. for over 15 years, with a PMA submitted to the FDA for U.S. approval [11][12] Market Position and Strategy - **Market Leadership**: Strong relationship with Johnson & Johnson, contributing to market leadership in OA pain management [7][8] - **Growth Strategy**: Focus on top-line growth through commercial channels and product pipeline development [3][21] - **Operational Discipline**: Emphasis on manufacturing efficiency and expense management to improve profitability [24] Challenges and Competitive Landscape - **Market Dynamics**: The HA market is maturing with increasing competition, particularly from hydrogels that offer longer-lasting solutions [25][30] - **Pricing Pressure**: OEM channel faced challenges due to pricing changes, impacting revenue in 2025 [19][20] Research and Development - **R&D Investment**: Ongoing investment in R&D for Cingal and other products in the pipeline, aiming to enhance product stability and effectiveness [32][33] - **Clinical Trials**: Cingal has completed three phase three trials demonstrating statistical significance against competitors [14] Future Outlook - **2026 Projections**: Anticipated revenue growth driven by international OA pain products and U.S. regenerative business [18][19] - **FDA Approvals**: Plans to launch Hyalofast in the U.S. pending FDA approval, contributing to future growth [18][22] Conclusion Anika Therapeutics is positioned for growth with a strong financial foundation, a diverse product portfolio, and a strategic focus on expanding its market presence while navigating competitive challenges in the medical device industry.

2026 CANACCORD GENUITY MUSCULOSKELETAL CONFERENCE MARCH 2, 2026 Anika. Restore Active Living. SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking ...

Core Insights - Anika Therapeutics reported improved profitability in Q4 2025, with GAAP gross margin increasing to 63% from 56% year-over-year, driven by a favorable product mix and higher manufacturing productivity [1] - The company outlined its strategic priorities under new CEO Steve Griffin, focusing on commercial growth, pipeline development, and operational efficiency [4] Financial Performance - For Q4 2025, operating expenses rose to $18.5 million from $17.8 million, with SG&A increasing due to higher sales and marketing expenses, while R&D remained flat at $6.5 million [1] - Full-year 2025 revenue was reported at $112.8 million, down 6% year-over-year, with commercial channel revenue increasing by 15% to $48.4 million, while OEM channel revenue declined by 17% to $64.4 million [6] - Adjusted EBITDA for 2025 was $5.3 million, approximately 5% of revenue, exceeding the revised outlook [8] Revenue Breakdown - OEM channel revenue for Q4 2025 was $17.3 million, a 12% decline year-over-year, attributed to lower pricing for Monovisc and Orthovisc [2] - Commercial channel revenue rose 22% to $13.3 million, driven by international growth and momentum in Integrity, with international OA pain management revenue increasing by 28% [3] Product and Pipeline Updates - Integrity procedures and revenue more than doubled to approximately $6 million for the year, marking its seventh consecutive quarter of growth [10] - Anika submitted the final module of its PMA for Hyalofast to the FDA, although the study did not meet all pre-specified endpoints [12] - Cingal surpassed one million injections across over 40 international markets, with ongoing studies in the U.S. [13] 2026 Outlook - For 2026, Anika expects total revenue between $114 million and $122.5 million, representing 1% to 9% year-over-year growth, with commercial channel revenue projected to grow 10% to 20% [14] - OEM channel revenue is anticipated to be flat to down 5%, reflecting pricing pressures [15] Organizational Changes - The company implemented a new organizational structure aimed at streamlining leadership and aligning resources with growth initiatives, expecting approximately $2.5 million in annualized headcount savings [17][18]

Financial Data and Key Metrics Changes - In Q4 2025, Anika generated total revenue of $30.6 million, flat year-over-year, consistent with revised full-year expectations [16] - For the full year 2025, total revenue was $112.8 million, a decline of 6% compared to the prior year [20] - GAAP gross margin increased to 63% from 56% in the prior year, reflecting higher revenue from international OA pain sales [18] - Total adjusted EBITDA from continuing operations was $4.5 million in Q4, higher than revised guidance [19] - For the full year, adjusted EBITDA was $5.3 million, or approximately 5% of revenue, outperforming the revised outlook of -3% to +3% [22] Business Line Data and Key Metrics Changes - Commercial channel revenue grew 22% in Q4, reaching $13.3 million, driven by strong international execution and Integrity's momentum [16] - International OA pain management revenue increased 28% in Q4 and 12% for the full year, reflecting strong market share gains [8] - Integrity revenue more than doubled to approximately $6 million in 2025, marking its seventh consecutive quarter of growth [9] - OEM channel revenue declined 12% in Q4 and 17% for the full year, primarily due to pricing pressures [9][17] Market Data and Key Metrics Changes - International OA pain management remained a key contributor, with strong growth across multiple regions [8] - The U.S. OA pain management pricing environment was challenging, impacting OEM revenue [9] Company Strategy and Development Direction - The company has three strategic priorities: revenue growth through the commercial channel, advancing the HA-based innovation pipeline, and improving operational execution [6][7] - Focus on expanding the international OA pain portfolio and scaling Integrity as a differentiated regenerative platform [6] - The company aims to strengthen operational execution through improved manufacturing and a streamlined organizational design [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver improved performance and long-term value, entering 2026 with clarity and momentum [28] - The company anticipates total revenue for 2026 to be between $114 million and $122.5 million, reflecting continued momentum in the commercial channel [26] - Adjusted EBITDA for 2026 is expected to be 5%-10% of revenue, supported by commercial channel growth and cost reduction actions [27] Other Important Information - The company ended 2025 with $57.5 million in cash and no debt, providing a strong liquidity position [23] - A $15 million stock repurchase plan was initiated in November 2025, with $10.7 million already purchased [24] Q&A Session Summary Question: Contribution from Hyalofast in 2027 - Management confirmed that approximately $3 million of anticipated revenue for Hyalofast in 2027 remains unchanged, contingent upon U.S. approval [30] Question: Normalized gross margin expectations - Management indicated that a normalized gross margin in the high 50s is appropriate for future planning [31] Question: Future free cash flow expectations - Management expects free cash flow in 2026 to be somewhat in line with 2025 results [35] Question: International OA pain market dynamics - Management noted sustained market share gains and growth in new markets, with no single market driving top-line growth [36] Question: OEM channel sequential improvement - Management attributed the sequential improvement to volume and end-user demand, with continued conversations with J&J regarding future market dynamics [40] Question: Timeline for Cingal's NDA filing - Management stated that the NDA filing timeline will depend on the enrollment of the bioequivalence study, which is currently ongoing [43] Question: Integrity's revenue growth expectations - Management expects strong double-digit growth for Integrity in 2026, although not at the same percentage increase as in 2025 [44] Question: Capital allocation priorities - Management emphasized that capital allocation will focus on manufacturing improvements and investments in the U.S. sales channel, with potential for future evaluations of M&A opportunities [53]

Financial Data and Key Metrics Changes - In Q4 2025, Anika generated total revenue of $30.6 million, flat year-over-year, consistent with revised full-year expectations [16] - Commercial channel revenue grew 22% to $13.3 million, driven by strong international execution and continued momentum in Integrity [16] - GAAP gross margin increased to 63% from 56% in the prior year, reflecting higher revenue from international OA pain sales and improved manufacturing productivity [18] - For the full year 2025, total revenue was $112.8 million, a decline of 6% compared to the prior year, with commercial channel revenue up 15% to $48.4 million [20][21] Business Line Data and Key Metrics Changes - International OA pain management revenue increased 28% in Q4 and 12% for the full year, reflecting strong execution and market share gains [8][20] - Integrity revenue more than doubled to approximately $6 million in 2025, marking its seventh consecutive quarter of growth [9][20] - OEM channel revenue declined 12% in Q4 and 17% for the full year, primarily due to pricing pressures in the U.S. market [9][21] Market Data and Key Metrics Changes - The international OA pain management portfolio, including Monovisc and Cingal, delivered strong growth, with significant share gains across multiple regions [8][20] - Hyalofast continued to gain traction outside the U.S., benefiting from its ease of use and differentiation [8] Company Strategy and Development Direction - The company has three strategic priorities: revenue growth through the commercial channel, advancing the HA-based innovation pipeline, and improving operational execution [6][7] - Focus on expanding the international OA pain portfolio and scaling Integrity as a differentiated regenerative platform [6] - The company aims to strengthen operational execution through improved manufacturing productivity and a streamlined organizational design [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver improved performance and long-term value, entering 2026 with clarity and momentum [28] - The company expects full-year revenue for 2026 to be between $114 million and $122.5 million, reflecting continued momentum in the commercial channel [26] - Adjusted EBITDA is expected to be 5% to 10% of revenue, supported by growth in the commercial channel and cost reduction actions [27] Other Important Information - The company ended 2025 with $57.5 million in cash and no debt, providing a strong liquidity position [23] - A $15 million stock repurchase plan was initiated in November 2025, with $10.7 million already purchased [23] Q&A Session Summary Question: Contribution from U.S. Hyalofast in 2027 - Management indicated that approximately $3 million of anticipated revenue for Hyalofast in 2027 remains contingent upon U.S. approval [30] Question: Normalized gross margin expectations for 2026 - Management expects normalized gross margins to be in the high 50s, acknowledging that the current quarter's margins may not be sustainable [31][32] Question: Free cash flow expectations for 2026 - Management anticipates free cash flow for 2026 to be somewhat in line with 2025 levels, considering restructuring elements [34][35] Question: Dynamics of international OA pain performance - Management noted sustained market share gains and growth in new markets, with no single market driving top-line growth [36] Question: Improvement in OEM channel despite pricing headwinds - Management attributed the sequential improvement in the OEM channel to volume and end-user demand, particularly for Monovisc [40] Question: Timeline for Cingal's NDA filing - Management stated that the NDA filing timeline will depend on the enrollment of the bioequivalence study, which is currently ongoing [42] Question: Revenue growth expectations for Integrity in 2026 - Management expects strong double-digit growth for Integrity in 2026, although not at the same variance percentage as in 2025 [44] Question: Capital allocation priorities - Management emphasized investments in manufacturing operations and U.S. sales channels as top priorities, with potential for future evaluations of M&A opportunities [53][55]

Financial Data and Key Metrics Changes - In Q4 2025, Anika generated total revenue of $30.6 million, flat year-over-year, with commercial channel revenue growing 22% to $13.3 million [18][19] - For the full year 2025, total revenue was $112.8 million, a decline of 6% compared to the prior year, while commercial channel revenue increased by 15% to $48.4 million [23][24] - GAAP gross margin improved to 63% in Q4 2025 from 56% in the prior year, while full-year gross margin was 57%, down from 63% in 2024 [20][24] Business Line Data and Key Metrics Changes - The international OA pain management business delivered 28% growth in Q4 2025, contributing significantly to the commercial channel's performance [9][19] - Integrity revenue more than doubled to approximately $6 million in 2025, marking its seventh consecutive quarter of growth [10][23] - OEM channel revenue declined 12% in Q4 and 17% for the full year, primarily due to pricing pressures [10][24] Market Data and Key Metrics Changes - International OA pain revenue increased 28% in Q4 and 12% for the full year, reflecting strong execution and market share gains [9][19] - The OEM channel faced challenges with a decline in revenue, attributed to a more challenging pricing environment in the U.S. [10][24] Company Strategy and Development Direction - The company has three strategic priorities: revenue growth through the commercial channel, advancing the HA-based innovation pipeline, and improving operational execution [6][8] - Focus on expanding the international OA pain portfolio and scaling Integrity as a differentiated regenerative platform [6][7] - The company aims to enhance manufacturing productivity and streamline operations to improve profitability and cash generation [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver improved performance and long-term value, entering 2026 with clarity and momentum [30][31] - The outlook for 2026 includes total revenue guidance of $114 million to $122.5 million, reflecting continued growth in the commercial channel [28][30] Other Important Information - The company generated $11.2 million in operating cash flow for 2025, an improvement over the previous year, and ended the year with $57.5 million in cash and no debt [26] - A $15 million stock repurchase plan was initiated in November 2025, with $10.7 million already purchased [26] Q&A Session Summary Question: Contribution from Hyalofast in 2027 - Management confirmed that approximately $3 million of anticipated revenue for Hyalofast in 2027 remains unchanged, contingent upon U.S. approval [34] Question: Normalized gross margin expectations - Management indicated that a normalized gross margin should be in the high 50s, acknowledging that the current quarter's margin is not sustainable in the near term [35][36] Question: Future free cash flow expectations - Management expects free cash flow in 2026 to be somewhat in line with 2025 levels, considering restructuring-related elements [37][39] Question: International OA pain dynamics - Management noted sustained market share gains and growth in new markets, with no single market driving top-line growth [40][41] Question: OEM channel sequential improvement - Management attributed the sequential improvement in the OEM channel to volume and end-user demand, with expectations for continued market share gains [44] Question: Timeline for Cingal's NDA filing - Management stated that the NDA filing timeline will depend on the enrollment of the bioequivalence study, which is currently ongoing [46] Question: Integrity's revenue growth in 2026 - Management expects strong double-digit growth for Integrity in 2026, although not at the same percentage increase as in 2025 [48] Question: Capital allocation priorities - Management emphasized that capital allocation focuses on delivering for patients and customers, with investments in manufacturing and U.S. sales channels being top priorities [57][59]

Q4 AND FULL YEAR 2025 EARNINGS CALL Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Se ...

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $27.8 million, a 6% decline compared to the same period in 2024 [16] - Adjusted EBITDA from continuing operations was positive at $900,000, a decline of $3.7 million year over year [22] - Gross margin was 56%, a decrease of 10 percentage points year over year, but an improvement of 5 percentage points sequentially from Q2 [19] Business Line Data and Key Metrics Changes - Commercial channel revenue grew 22% year over year to $12 million, driven by a 25% increase in regenerative solutions [16][18] - OEM channel revenue declined 20% to $15.8 million, primarily due to pricing pressure [18] - Integrity procedures in the U.S. grew for the sixth consecutive quarter, with a projected doubling of procedures and revenue in 2025 compared to last year [7][17] Market Data and Key Metrics Changes - International OA pain management revenue grew 21% year over year, with year-to-date growth at 6% [9][18] - Cingal injections surpassed 1 million since its launch in 2016, indicating strong uptake outside the U.S. [9] Company Strategy and Development Direction - The company is focused on executing its product growth strategy and enhancing operational performance to create shareholder value [14] - A second $15 million share repurchase program has been initiated, reflecting a commitment to returning capital to shareholders [24] - The company is advancing toward key regulatory milestones, including the NDA submission for Cingal and the PMA submission for Hyalofast [14][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the OA pain management business despite Johnson & Johnson's separation of its orthopedic business [6] - The company anticipates flat to modestly lower revenue in the OEM channel due to ongoing pricing pressure but expects unit volume growth to offset this [18] - Management remains focused on improving expense profiles to deliver positive operating cash flow and sustainable returns for shareholders [25] Other Important Information - The third and final PMA module for Hyalofast was submitted to the FDA, marking a significant milestone [10] - The company has streamlined its organizational structure following two divestitures earlier in 2025, leading to a 12% reduction in SG&A expenses [20][21] Q&A Session Summary Question: What are the priorities for increasing Integrity utilization? - Management indicated a balanced focus on acquiring new surgeons and training existing ones to drive utilization [29][31] Question: What is the timeline for Cingal bioequivalents and toxicity studies? - Management stated that the timeline will be clearer after the bioequivalent study begins, expected by the end of the year [32] Question: How does the company prioritize capital deployment? - The hierarchy includes internal investments in product growth, CapEx for manufacturing support, and share repurchase, with M&A not currently prioritized [33][35] Question: Are production issues fully resolved? - Management confirmed that production issues were a hangover from earlier disruptions but are expected to be resolved by year-end [36] Question: What are the expectations for gross margin in Q4? - Management indicated that gross margin in Q4 is expected to be between current levels and slightly higher, depending on recovery from shipping dynamics [37]

Financial Performance - Commercial Channel Revenue increased by 22% year-over-year[8] - OEM Revenue decreased by 20% due to lower pricing both in transfer units and royalties on Monovisc® and Orthovisc® sales controlled by J&J MedTech[12, 14] - Total Revenue decreased by 6% to $278 million[12, 14] - Gross Profit decreased due to lower OEM Channel revenue and higher manufacturing costs[14] - SG&A expenses decreased by 12% reflecting cost discipline[8, 12] - Adjusted EBITDA was $09 million[8] - Cash provided by operations totaled $69 million[8] Product and Pipeline Updates - Regenerative Solutions portfolio grew 25% year-over-year[8] - International OA Pain business grew 21% year-over-year[8] - Integrity Implant System continues to outpace the market with approximately 500 cases in Q3[8, 11] - Hyalofast® PMA was submitted on October 31, supported by U S Phase III data[8] Strategic Initiatives - Commenced a $15 million 10b5-1 share repurchase program[8]